Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we discuss our current understanding of the molecular events controlling cellular metabolism downstream of PI3K and AKT and of how these events couple two major hallmarks of cancer: growth factor independence through oncogenic signalling and metabolic reprogramming to support cell survival and proliferation.
|
31686003 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Herein, in silico structure- and ligand-based approaches have been applied to screen in-house IIIM natural product repository for Akt1 (serine/threonine protein kinases) which is a well-known therapeutic target for cancer due to its overexpression and preventing the cells from undergoing apoptosis.
|
30798436 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Frequent mutation of PI3K/AKT/mTOR signaling pathway genes in human cancers has stimulated large investments in targeted drugs but clinical successes are rare.
|
31812693 |
2020 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
ACLY plays a pivotal role in cancer metabolism through the potential deprivation of cytosolic citrate, a process promoting glycolysis through the enhancement of the activities of PFK 1 and 2 with concomitant activation of oncogenic drivers such as PI3K/AKT which activate ACLY and the Warburg effect in a feed-back loop.
|
31830561 |
2020 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Here we provide a comprehensive review of the current knowledge on SOX2 protein modifications, their proposed relationship to the PI3K/AKT pathway, and regulatory influence on SOX2 with regards to stemness, reprogramming, and cancer.
|
31477842 |
2020 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Additionally, activation of AKT reversed the nalbuphine-induced inhibition of cancer stem-like properties, tumorigenesis and EMT.
|
31092275 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The Pim and AKT serine/threonine protein kinases are implicated as drivers of cancer.
|
31548394 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The serine-threonine kinase AKT/PKB is a critical regulator of various essential cellular processes, and dysregulation of AKT has been implicated in many diseases, including cancer.
|
30643008 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Receptor tyrosine kinases upstream of PI3K, the p110a catalytic fractional unit of PI3K, the downstream kinase, AKT, and therefore the negative regulator, PTEN, are all often altered in cancer.
|
30849534 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
PD-1 activity within malignant T cells can negatively regulate the PI3K/AKT and PKCθ/NF-κB tumor survival pathways and PD-1 is frequently inactivated in this human malignancy.
|
30979616 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Among the relevant biological pathways, phosphatidylinositol 3-kinase/AKT (PIK3/AKT)-mammalian target of rapamycin (mTOR) signaling is frequently upregulated in this cancer.
|
30574817 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The PI3K-AKT-mTOR pathway is often a commonly disrupted pathway in human cancer and, therefore, it is widely exploited for cancer therapy.
|
31247018 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Chronic <i>Helicobacter pylori</i> infection increases the risk of gastric cancer and induction of hypoxia-induced factor (HIF), which is frequently associated with the development and progression of several types of cancer.We recently showed that <i>H. pylori</i> activation of the PI3K-AKT-mTOR pathway in gastric cells increased HIF-1α expression.Here, we identified the <i>H. pylori</i> virulence factor responsible for HIF-1α induction.A mutant of the <i>H. pylori</i> 84-183 strain was identified with reduced ability to induce HIF-1α.
|
31185594 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
K-Ras<sup>G12V/Y40C</sup>-PI3K/AKT pathway regulates H1.4<sup>S35ph</sup> through PKA to promote the occurrence and development of osteosarcoma cancer.
|
31126199 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Although <i>PIK3CA</i> amplification associates with some surrogate measures of increased PI3K activity, markers for AKT1-3 and MTOR signaling are decreased, suggesting that this signaling is not a predominant pathway to promote cancer growth of aggressive serous-like UCEC.
|
30442683 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
We concluded that MAPK4 can promote cancer by activating the AKT/mTOR signaling pathway and that targeting MAPK4 may provide a novel therapeutic approach for cancer.
|
30688659 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
<b>K1</b> serves to downregulate various cancer survival signaling pathways (AKT, p38, IL-6, VEGF, and TNF-α) and upregulate an anti-inflammatory response (IL-10).
|
31509395 |
2019 |
Malignant Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Studies in mammals indicate a role for VEPH1 in modulating TGFβ signaling and AKT activation, while numerous studies indicate VEPH1 expression is altered in several pathological conditions, including cancer.
|
31500637 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
These results elucidate that the inhibition of NF-ҡ B and PI3K/AKT is one of the most important mechanism by which BCP suppresses cancer cell proliferation and enhances apoptosis.
|
31583906 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
TMEM206 promotes the malignancy of colorectal cancer cells by interacting with AKT and extracellular signal-regulated kinase signaling pathways.
|
30417481 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Inhibition of AKT Sensitizes Cancer Cells to Antineoplastic Drugs by Downregulating Flap Endonuclease 1.
|
31467180 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
MicroRNA-429 inhibits cancer cell proliferation and migration by targeting the AKT1 in melanoma.
|
31322550 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Targeting AKT for cancer therapy.
|
31594388 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Hyperactivated AKT kinase due to loss of its negative regulator PTEN influences many aspects of cancer biology, including chromatin.
|
30446585 |
2019 |
Malignant Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Molecular genetic aberrations in the phosphoinositide 3-kinase (PI3K)/protein kinase B (AKT)/mammalian target of rapamycin (mTOR) pathway are common in human cancers including glioblastoma, yet, novel therapeutic approaches targeting this pathway in glioblastoma have not been successful.
|
31618458 |
2019 |